› 4j3y

X-ray diffraction
1.45Å resolution

Crystal structure of XIAP-BIR2 domain

Released:
DOI: 10.2210/pdb4j3y/pdb
PDB entry 4j3y coloured by chain, front view.
PDB entry 4j3y coloured by chain, side view.
PDB entry 4j3y coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
The structure of XIAP BIR2: understanding the selectivity of the BIR domains.
Lukacs C, Belunis C, Crowther R, Danho W, Gao L, Goggin B, Janson CA, Li S, Remiszewski S, Schutt A, Thakur MK, Singh SK, Swaminathan S, Pandey R, Tyagi R, Gosu R, Kamath AV, Kuglstatter A
Acta Crystallogr D Biol Crystallogr 69 1717-25 (2013)
PMID: 23999295

Function and Biology Details

Reaction catalysed: 
S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine
Biochemical function:
Biological process:
Cellular component:
  • not assigned
Sequence domain:

Structure analysis Details

Assembly composition:
homo dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-161372 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
E3 ubiquitin-protein ligase XIAP Chains: A, C
Molecule details ›
Chains: A, C
Length: 86 amino acids
Theoretical weight: 9.94 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P98170 (Residues: 152-236; Coverage: 17%)
Gene names: API3, BIRC4, IAP3, XIAP
Sequence domains: Inhibitor of Apoptosis domain
Structure domains: Inhibitor Of Apoptosis Protein (2mihbC-IAP-1); Chain A

Ligands and Environments

1 bound ligand:
Ligand ZN 2 x ZN
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: SLS BEAMLINE X10SA
Spacegroup: I422
Unit cell:
a: 74.461Å b: 74.461Å c: 108.683Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.185 0.184 0.203
Expression system: Escherichia coli

Quick links

Citations

3 review citations

X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy.
Obexer et al. (2014)
2 more

5 mentions without citation

Molecular modeling in the age of clinical genomics, the enterprise of the next generation.
Prokop et al. (2017)
4 more